These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 2432675

  • 1. Thrombin inhibitory activity of heparin cofactor II depends on the molecular weight and sulfate amount of dextran sulfate.
    Yamagishi R, Niwa M, Sakuragawa N.
    Thromb Res; 1986 Nov 01; 44(3):347-54. PubMed ID: 2432675
    [Abstract] [Full Text] [Related]

  • 2. Binding of heparin or dermatan sulfate to thrombin is essential for the sulfated polysaccharide-accelerated inhibition of thrombin by heparin cofactor II.
    Yamagishi R, Koide T, Sakuragawa N.
    FEBS Lett; 1987 Dec 10; 225(1-2):109-12. PubMed ID: 3691797
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Antithrombin activity of fucoidan. The interaction of fucoidan with heparin cofactor II, antithrombin III, and thrombin.
    Church FC, Meade JB, Treanor RE, Whinna HC.
    J Biol Chem; 1989 Feb 25; 264(6):3618-23. PubMed ID: 2914965
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Kinetic analysis of various heparin fractions and heparin substitutes in the thrombin inhibition reaction.
    Pletcher CH, Cunningham M, Nelsestuen GL.
    Biochim Biophys Acta; 1985 Jan 28; 838(1):106-13. PubMed ID: 2578296
    [Abstract] [Full Text] [Related]

  • 8. Activation of heparin cofactor II by dermatan sulfate.
    Tollefsen DM, Pestka CA, Monafo WJ.
    J Biol Chem; 1983 Jun 10; 258(11):6713-6. PubMed ID: 6687888
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Activation of heparin cofactor II by fibroblasts and vascular smooth muscle cells.
    McGuire EA, Tollefsen DM.
    J Biol Chem; 1987 Jan 05; 262(1):169-75. PubMed ID: 3793724
    [Abstract] [Full Text] [Related]

  • 11. Mechanism of thrombin inhibition by heparin cofactor II in the presence of dermatan sulphates, native or oversulphated, and a heparin-like dextran derivative.
    Maaroufi RM, Jozefowicz M, Tapon-Bretaudière J, Jozefonvicz J, Fischer AM.
    Biomaterials; 1997 Feb 05; 18(4):359-66. PubMed ID: 9068899
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of chymotrypsin by heparin cofactor II.
    Church FC, Noyes CM, Griffith MJ.
    Proc Natl Acad Sci U S A; 1985 Oct 05; 82(19):6431-4. PubMed ID: 3863104
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Abolition by dextran sulfate of the heparin-accelerated antithrombin III/thrombin reaction.
    Oshima G, Nagai T, Nagasawa K.
    Thromb Res; 1984 Sep 15; 35(6):601-11. PubMed ID: 6209818
    [Abstract] [Full Text] [Related]

  • 17. Mutagenesis of thrombin selectively modulates inhibition by serpins heparin cofactor II and antithrombin III. Interaction with the anion-binding exosite determines heparin cofactor II specificity.
    Sheehan JP, Wu Q, Tollefsen DM, Sadler JE.
    J Biol Chem; 1993 Feb 15; 268(5):3639-45. PubMed ID: 8429040
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.